Fulcrum Therapeutics, Inc. (FULC)

Market Cap	161.28M
Revenue (ttm)	80.87M
Net Income (ttm)	-17.91M
Shares Out	53.94M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	731,597
Open	2.980
Previous Close	3.010
Day's Range	2.955 - 3.060
52-Week Range	2.865 - 13.700
Beta	2.23
Analysts	Hold
Price Target	7.44 (+148.83%)
Earnings Date	Nov 13, 2024

About FULC

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discove...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2019
• Employees: 76
• Stock Exchange: NASDAQ
• Ticker Symbol: FULC
• Website: https://www.fulcrumtx.com

Financial Performance

In 2023, Fulcrum Therapeutics's revenue was $2.81 million, a decrease of -55.77% compared to the previous year's $6.34 million. Losses were -$97.34 million, -11.41% less than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for FULC stock is "Hold." The 12-month stock price forecast is $7.44, which is an increase of 148.83% from the latest price.

Price Target

$7.44

(148.83% upside)

Analyst Consensus: Hold